Skip to content

Skeletal muscle protein synthesis in elderly after bolus intake of oral nutritional supplements.

Skeletal muscle protein synthesis in elderly after bolus intake of oral nutritional supplements.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON19903
Enrollment
20
Registered
2009-05-19
Start date
2009-05-19
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generally healthy elderly

Interventions

1. Duration of intervention: 8 hours
2. Intervention group: 8 hours
3. Control group: 8 hours.

Sponsors

Danone Research – Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Generally healthy male or female; 2. Ability to walk, sit down, and stand up independently; 3. Age 60 years or older; 4. BMI between 21 and 30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Co-morbidities: A. Any (history of) gastrointestinal disease that interferes with GI function; B. Diagnosed and active treatment of Diabetes Mellitus type I or II; C. History of congestive heart failure, or recent (6 months) hospitalization for heart disease treatment or management (e.g. PTCA, stent, surgery), or myocardial infarction in the past year. 2. Infection or fever in the last 7 days; 3. Medication: A. Use of antibiotics within 3 weeks prior to the study visit; B. Current use of corticosteroids, growth hormone, or testosterone. 4. Dietary or life style characteristics: A. Adherence to a weight loss diet; B. Use of protein containing or amino acid containing nutritional supplements within one week of study entry; C. Current participation in muscle strengthening program. 5. Contraindications to biopsy procedure: A. Platelet count (PLT) < 100,000; B. History of hypo- or hyper-coagulation disorders including use of a coumarin derivative, history of deep venous thrombosis (DVT), or pulmonary embolism (PE) at any point in lifetime; C. Currently taking anti-thrombotics and cannot stop for 7 days (i.e. medical indication); D. Allergy to local anaesthetic. 6. Blood hemoglobin < 9.0 g/dL.

Design outcomes

Primary

MeasureTime frame
Muscle protein synthesis rate.

Secondary

MeasureTime frame
Plasma amino acids, insulin, and glucose levels.

Contacts

Public ContactR. Memelink
robert.memelink@danone.com/r.g.memelink@hva.nl+31 (0)317 467972

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)